CASTLE BIOSCIENCES INC (CSTL)

Notable Friday Option Activity: ENVX, OKTA, CSTL

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024

CSTL stock results show that Castle Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Castle Biosciences (NASDAQ:CSTL) just reported results for the first quarter of...

Castle Biosciences Reports First Quarter 2024 Results

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

CSTL Makes Notable Cross Below Critical Moving Average

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Commit To Buy Castle Biosciences At $15, Earn 11.8% Annualized Using Options

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Castle Biosciences Announces Updates to its Board of Directors

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Thursday Sector Laggards: Medical Instruments & Supplies, Diagnostics

Castle Biosciences files for $300M mixed securities shelf (NASDAQ:CSTL)

Castle Biosciences (CSTL) files prospectus; an overview of the filing and its implications for investors in the financial market.

Castle Biosciences GAAP EPS of -$0.10 beats by $0.46, revenue of $66.12M beats by $4.95M (NASDAQ:CSTL)

Castle Biosciences reports Q4 2023 results with a beat on GAAP EPS and revenue.

Notable Wednesday Option Activity: MSFT, EDIT, CSTL

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report

Castle Biosciences raises FY23 revenue, to exceed $210M above consensus

Castle Biosciences expects to exceed its revenue guidance for fiscal year 2023, delivering over $210 million.

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

Commit To Purchase Castle Biosciences At $20, Earn 26.9% Annualized Using Options

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)